Advertisement

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: Results from a phase 2a study

Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyère Mahuzier, Brian Gadbaw and Yesim Aydinok

Article Information

PubMed 

Print ISSN 
Online ISSN 


Contributors 
  • Ali T. Taher, 1 American University of Beirut Medical Center, Lebanon;
  • Zeynep Karakas, 2 Department of Pediatric Hematology and Oncology, Istanbul University, Istanbul Medical Faculty, Turkey;
  • Elena Cassinerio, 3 Universita di Milano, Ca Granda Foundation IRCCS, Italy;
  • Noppadol Siritanaratkul, 4 Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand;
  • Antonis Kattamis, 5 First Department of Pediatrics, University of Athens, Greece;
  • Aurelio Maggio, 6 Campus of Haematology Franco e Piera Cutino A. O.O.R., Villa Sofia V. Cervello, Palermo, Italy;
  • Stefano Rivella, 7 Department of Pediatrics, Division of Hematology, Children's Hospital of Philadelphia, United States;
  • Norbert Hollaender, 8 Novartis Pharma AG, Basel, Switzerland;
  • Bruyère Mahuzier, 9 Novartis Pharma S.A.S, Rueil Malmaison, France;
  • Brian Gadbaw, 10 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States;
  • Yesim Aydinok, 11 Ege University Hospital, Department of Pediatric Hematology and Oncology, Izmir, Turkey

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output